Effectiveness and Safety of Finerenone in Chinese CKD Patients Without Diabetes Mellitus - Trial NCT06301022
Access comprehensive clinical trial information for NCT06301022 through Pure Global AI's free database. This phase not specified trial is sponsored by First Affiliated Hospital of Harbin Medical University and is currently Recruiting. The study focuses on Chronic Kidney Diseases. Target enrollment is 90 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
First Affiliated Hospital of Harbin Medical University
Timeline & Enrollment
N/A
Dec 15, 2022
Dec 31, 2024
Primary Outcome
24 hours urinary total protein,estimate Gromerular filtration rate,serum potassium
Summary
Background๏ผ This study aimed to evaluate the effectiveness and safety of Finerenone in
 patients with chronic kidney disease (CKD) without diabetes mellitus(DM), however, evidence
 based on both clinical trails and real-world data are limited.
 
 Methods:
 
 Patients with CKD without DM were enrolled in this study from December 2022 to December 2024.
 In conjunction with the established treatment regimen for chronic kidney disease (CKD), study
 participants were additionally administered Finerenone. To evaluate the therapeutic impact
 and safety profile of the intervention, three primary biomarkers were monitored: 24-hour
 urinary protein (UTP), estimated glomerular filtration rate (eGFR), and serum potassium
 (sK+). These parameters were closely measured on a monthly basis, starting from the point of
 enrollment and continuing for a duration of twelve months or possibly longer.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06301022
Non-Device Trial